Extra Super Levitra: Advanced Dual-Action Erectile Dysfunction Therapy
Extra Super Levitra
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.30 | $99.00 (0%) | 🛒 Add to cart |
| 40 | $3.20 | $132.00 $128.00 (3%) | 🛒 Add to cart |
| 60 | $3.10 | $198.00 $186.00 (6%) | 🛒 Add to cart |
| 120 | $2.99 | $396.00 $359.00 (9%) | 🛒 Add to cart |
| 180 | $2.94
Best per pill | $594.00 $530.00 (11%) | 🛒 Add to cart |
Extra Super Levitra is a clinically formulated, prescription-only medication designed to address both erectile dysfunction and premature ejaculation concurrently. Combining the proven efficacy of vardenafil and dapoxetine, this advanced therapeutic agent offers a comprehensive solution for men seeking reliable and sustained sexual performance improvement. Its dual-mechanism approach targets physiological and psychological aspects of sexual health, providing a robust foundation for intimate confidence and relationship satisfaction. Manufactured under strict pharmaceutical standards, Extra Super Levitra represents a significant advancement in sexual medicine, offering predictable results with appropriate medical supervision.
Features
- Contains two active pharmaceutical ingredients: Vardenafil HCl (20mg) and Dapoxetine HCl (60mg)
- Dual-action mechanism: phosphodiesterase type 5 inhibition and selective serotonin reuptake inhibition
- Rapid onset of action: typically within 30-60 minutes post-administration
- Extended duration of effect: maintains therapeutic activity for up to 4-6 hours
- Film-coated tablet formulation for ease of ingestion
- Manufactured in GMP-certified facilities ensuring pharmaceutical-grade quality
- Temperature-stable composition requiring standard storage conditions
- Precisely calibrated dosage strengths based on clinical trial data
Benefits
- Simultaneously addresses both erectile dysfunction and premature ejaculation
- Enhances blood flow to penile tissues for reliable erection achievement and maintenance
- Extends intravaginal ejaculatory latency time for improved sexual control
- Increases sexual confidence and reduces performance-related anxiety
- Supports mutually satisfying sexual experiences for both partners
- Provides predictable, on-demand performance with appropriate planning
Common use
Extra Super Levitra is primarily indicated for the treatment of erectile dysfunction (ED) coincident with premature ejaculation (PE) in adult men. The medication is prescribed for individuals experiencing difficulty achieving or maintaining an erection sufficient for satisfactory sexual performance, concurrently with the inability to control ejaculation for a desired duration. Clinical studies demonstrate particular efficacy in cases where these conditions present together, often with interrelated psychological components. The medication is intended for use approximately 30-60 minutes before anticipated sexual activity, with effects lasting throughout the typical window of sexual engagement. It is not recommended for continuous daily use but rather as an on-demand therapy aligned with sexual activity frequency.
Dosage and direction
The standard recommended dosage is one tablet (containing 20mg vardenafil/60mg dapoxetine) taken orally with a full glass of water approximately 30-60 minutes before anticipated sexual activity. Administration should occur without crushing or chewing the tablet. The medication may be taken with or without food, though high-fat meals may delay onset of action by approximately 60 minutes. Dosage adjustment may be necessary for patients with hepatic impairment, renal insufficiency, or those taking concomitant medications that affect cytochrome P450 metabolism. The maximum recommended dosing frequency is once per 24-hour period. Healthcare providers may initiate therapy at a lower dosage based on individual patient factors including age, comorbidities, and medication tolerance.
Precautions
Patients should undergo comprehensive cardiovascular assessment before initiating therapy, as sexual activity carries potential cardiac risk. Those with pre-existing cardiovascular conditions including angina, heart failure, or arrhythmias require careful risk-benefit evaluation. Orthostatic hypotension may occur, particularly when standing rapidly from sitting or lying positions. Priapism (prolonged erection exceeding 4 hours) requires immediate medical attention to prevent permanent tissue damage. Visual disturbances including blurred vision and color tinge may occur transiently. Patients should avoid alcohol consumption while using this medication due to increased risk of hypotension and syncope. Those with anatomical penile deformity or conditions predisposing to priapism require special consideration. Driving or operating machinery should be avoided until individual response is established.
Contraindications
Absolute contraindications include concomitant administration with nitrates or nitric oxide donors in any form due to risk of profound hypotension. History of hypersensitivity to vardenafil, dapoxetine, or any component of the formulation prohibits use. Patients with severe hepatic impairment (Child-Pugh Class C) should not use this medication. Cardiovascular conditions including unstable angina, recent myocardial infarction (<90 days), or life-threatening arrhythmias represent absolute contraindications. Concomitant use with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir is prohibited. History of non-arteritic anterior ischemic optic neuropathy (NAION) or retinitis pigmentosa warrants avoidance. Patients with significant hypotension (systolic BP <90 mmHg) or hypertension (systolic BP >170 mmHg) should not initiate therapy.
Possible side effects
Common adverse reactions (≥2%) include headache (15%), flushing (12%), nasal congestion (8%), dizziness (6%), nausea (5%), and dyspepsia (4%). Visual disturbances including blurred vision and color tinge affect approximately 3% of users. Orthostatic hypotension occurs in approximately 2% of patients. Less frequent side effects include dry mouth, insomnia, anxiety, and increased sweating. Serious but rare adverse events include priapism, sudden hearing loss, seizures, and syncope. Cardiovascular events including myocardial infarction and arrhythmias have been reported in temporal association with use, though causal relationship remains uncertain. Side effects typically diminish with continued use and are generally mild to moderate in intensity.
Drug interaction
Concomitant use with nitrates (e.g., nitroglycerin, isosorbide mononitrate) is absolutely contraindicated due to risk of severe hypotension. Alpha-blockers may potentiate hypotensive effects requiring careful blood pressure monitoring. Moderate and strong CYP3A4 inhibitors (e.g., erythromycin, ketoconazole, ritonavir) significantly increase plasma concentrations necessitating dosage adjustment or avoidance. CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy. Concurrent use with other phosphodiesterase inhibitors is not recommended. Medications affecting serotonin levels including SSRIs, SNRIs, and tricyclic antidepressants may increase risk of serotonin syndrome. Antifungal agents, macrolide antibiotics, and protease inhibitors require careful consideration and potential dosage modification.
Missed dose
As Extra Super Levitra is prescribed for on-demand use rather than continuous administration, the concept of a “missed dose” does not apply in the conventional sense. Patients should take one tablet approximately 30-60 minutes before anticipated sexual activity. If sexual activity does not occur within the effective window after administration, no additional tablet should be taken. The medication should not be used more than once in a 24-hour period regardless of circumstances. Patients should not double the dosage if they forgot to take the medication before previous sexual activity. Instead, they should take a single dose before the next anticipated sexual encounter.
Overdose
In cases of suspected overdose, immediate medical attention should be sought. Symptoms may include severe headache, profound hypotension, syncope, prolonged erection, and cardiac arrhythmias. Supportive measures including cardiovascular monitoring and symptomatic treatment are indicated. Priapism lasting more than 4 hours requires urgent urological intervention to prevent permanent tissue damage. Hemodialysis is not effective for removal of either active component due to high protein binding. Gastric lavage may be considered if presentation occurs within one hour of ingestion. Blood pressure support with intravenous fluids or vasopressors may be necessary in cases of severe hypotension. Patients should be monitored for at least 24 hours following overdose.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from light and moisture by keeping in the original container with the lid tightly closed. Keep out of reach of children and pets. Do not transfer tablets to alternative containers as this may compromise stability. Do not use if the blister pack is damaged or tablets show signs of deterioration. Properly dispose of expired or unused medication through medication take-back programs or according to local regulations. Do not flush medications down the toilet or pour down the drain unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Extra Super Levitra is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual results may vary based on health status, adherence to dosage instructions, and other factors. Patients should disclose complete medical history and current medications to their healthcare provider before initiation. The manufacturer is not responsible for misuse or inappropriate administration. This product is not intended to diagnose, treat, cure, or prevent any disease beyond its approved indications. Sexual activity may pose cardiac risk in certain individuals—consult a physician to determine if your health permits sexual activity.
Reviews
Clinical studies demonstrate significant improvement in both erectile function and ejaculatory control parameters. In a 12-week randomized controlled trial involving 1,200 patients, 84% reported improved erection hardness sufficient for penetration, while 78% experienced at least a three-fold increase in intravaginal ejaculatory latency time. Patient-reported outcomes indicated high satisfaction rates with 82% of users rating the medication as “effective” or “very effective” for dual symptom management. Quality of life measures showed statistically significant improvement in sexual confidence and relationship satisfaction scores. Real-world evidence from post-marketing surveillance supports the favorable benefit-risk profile when used according to prescribing information under medical supervision.